99mTc-MIP-1405

Drug Profile

99mTc-MIP-1405

Alternative Names: 99mTc-MIP1405; MIP-1405

Latest Information Update: 16 Jun 2012

Price : $50

At a glance

  • Originator Molecular Insight Pharmaceuticals
  • Class Radiopharmaceutical diagnostics; Radiopharmaceuticals; Small molecules; Technetium compounds
  • Mechanism of Action Antigen inhibitors; Diagnostic imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Prostate cancer

Most Recent Events

  • 14 Jun 2012 Discontinued - Phase-I for Prostate cancer in USA (IV)
  • 14 Jun 2012 Efficacy and pharmacokinetics data from a phase I trial in Prostate cancer (diagnosis) released by Molecular Insight Pharmaceuticals
  • 19 Oct 2011 Phase-I clinical trials in Prostate cancer in USA (IV; injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top